Peptides Dossier — citation verifiedPeptides Dossier.
Decide

Decide

Most peptide questions are decision questions, not research questions. “Does BPC-157 work?” usually means “is BPC-157 the right tool for me, for this specific goal, right now?”

Each guide below compares the realistic options for a goal — peptide, drug, and lifestyle — with effect sizes from the published literature, honest hedging where the evidence is thin, and the upstream interventions the marketing rarely talks about. No vendor links. No financial conflict of interest.

Decision guides
37
Discontinuation playbooks
4
Total
41
01·Goal-oriented decision guides

Pick the goal. Compare the options. Decide.

One guide per major goal. Public preview is the comparison table and framing; members get the per-option deep dive, the founder-voice "what I'd do in your shoes," and the operational notes for any self-experimenter running a structured cycle.

02·Discontinuation playbooks

Coming off — what to expect and how to taper

The conversation most peptide and pharmacological coverage skips. For chronic protocols (GLP-1 agonists, GH-axis stacks, TRT, MK-677 long-cycle), the rebound trajectory on discontinuation is the central feature of how the drug works, not a side effect. These playbooks walk the structured taper, the week-by-week off-drug timeline, biomarker recovery, and the behavioral substrate that determines where you land.

··How these guides are written

  • — Each guide compares peptide, drug, and lifestyle options on a consistent set of dimensions: evidence tier, effect size, time to outcome, cost, side effects, rebound risk, who should consider, who should skip.
  • — Cited primary literature where it exists. Honest hedging where it doesn't. No fabricated citations.
  • — Lifestyle interventions appear in every table, often as the highest-leverage row. This is the load-bearing observation across the category.
  • — No vendor links for peptides. No affiliate relationships. Lab referrals (Function Health, Marek, Quest, primary care) are mentioned because they're how you'd track outcomes — not as paid placements.
  • — Members get the deeper per-option analysis, founder-voice scenario walkthroughs, and operational notes for self-experimenters.